EUDA EUDA
Company Profile ↓Company Overview
EUDA (EUDA) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -6.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -6.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -6.67% |
| 1 Year: | -6.67% |
Stock Price Performance
| 1 Year: | -71.59% |
| 6 Months: | -27.67% |
| 3 Months: | +5.55% |
| 1 Month: | +37.83% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)55.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -6.7% CAGR over 5 years.
- Trading 77.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Apr 2021 | Oct 2021 | Jan 2022 | Mar 2022 | Apr 2022 | Oct 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 2.67M | - | - | 1.70M |
| Gross Profit | - | - | - | 1.27M | - | - | 403.60K |
| Operating Income | -7.85K | -45.59K | -225.64K | 75.31K | -481.64K | -298.33K | -1.98M |
| Net Income | -7.85K | -45.59K | -224.89K | 222.59K | -472.99K | 201.01K | -2.41M |
| Diluted EPS | - | - | - | 0.02 | - | - | -0.12 |
| R&D Expense | - | - | - | 2.95K | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Jul 2022 | Dec 2022 |
|---|---|---|---|
| Revenue | 10.54M | - | 9.84M |
| Gross Profit | 4.24M | - | 3.35M |
| Operating Income | -1.23M | -1.99M | -12.06M |
| Net Income | 864.83K | -1.76M | -24.88M |
| R&D Expense | 129.26K | - | 17.21K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Jul 2021 | Dec 2021 | Jul 2022 | Dec 2022 |
|---|---|---|---|---|---|
| Total Assets | - | 428.92K | 8.00M | 86.78M | 25.63M |
| Total Equity | -317.36K | 29.12K | 521.23K | -3.72M | -3.52M |
| Cash & Equivalents | - | - | 190.00K | 193.55K | 143.02K |
| Total Liabilities | - | 399.80K | 7.40M | 4.73M | 29.14M |
| Current Liabilities | - | - | 7.32M | - | 29.12M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Jul 2022 | Dec 2022 |
|---|---|---|---|
| Operating Cash Flow | 443.92K | -1.01M | -1.53M |
| Investing Cash Flow | -356.18K | -86.25M | -268.21K |
| Financing Cash Flow | -168.37K | 87.45M | 2.49M |
| Capital Expenditure | -1.96K | - | -18.14K |
| Free Cash Flow | 441.96K | - | -1.54M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Jul 2022 | Dec 2022 |
|---|---|---|---|
| Gross Margin % | 40.3% | - | 34.1% |
| Operating Margin % | -11.6% | - | -122.5% |
| Net Margin % | 8.2% | - | -252.9% |
| ROE % | 165.9% | 47.3% | 706.8% |
| ROCE % | -179.8% | - | 345.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for EUDA
EUDA Health (NASDAQ: EUDA) outlines oncology cell therapy plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNSExVZGRiajJHTDQ2NWJKQmFqY3NaTUpMSFdQQ214NldfNkxJcE4yNDBYeDcxdnpCdmZEaWJfM1RWWEpUcW5xMV8td19YVTRCUW9rUjhQZm14b1E4WkJvVFM5V2ZMdnVsWlJqT2d1d1A1UnhTdGRuWlU3Q0o1eEpTVVYwS1pfZFoza2VsNF…
EUDA Stock Price and Chart — NASDAQ:EUDA - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1LcnZvdG1xNHotSFJlWGJ5SUJuWVlHdWRLdkNKOXU1d3FwNUNjSy1fMW9ibnJ6Q3VMa2prenRCSFBUS29KcHloQTNEWlFOaHFkLVVuVGVVOXdrdF9R?oc=5" target="_blank">EUDA Stock Price and Chart — NASDAQ:EUDA</a…
EUDA Health Holdings Limited Receives Nasdaq MVLS Notice with 180-Day Compliance Period to Regain Listing Status | EUDA Stock News - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxNNnhRMjlqZlp6MUJpVmU1ZzdvTTRUcjFCTVZXM2tzYUl3UFBlckNqcU5ndnJibDZyWXAyYUlOQWhoLXdYbHl5QTNJWUxoMVJMV2wweFhiSUtKeENfb3Y2WEp6NUYydzVPeFhYOFIxdC1rYzVIMlBHVVNwVUY5ckJXcmpKZ2NQT2MxOEt4WV…
12 Health Care Stocks Moving In Friday's Intraday Session - EUDA Health Holdings (NASDAQ:EUDA), Forte Bio - Benzinga
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNMlpFN1FaNTRLX3ItQmtGSXctbHlFZzJIQlN0allpVkNnaFNjOXl3MExQZmdHMUVCeHBsb3ZuTmQ3ejY1TnB1N19uQjZDaUNONDBVelhSMVA4ZmRpcjIxX3lQQlozMjRtS1k3SzBOUEQtd05XaUpEZ2JxWVE1bkgwZGZWcUhEcXRCQnctaj…
EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPdjAyN2dqckQtR09jd2pPRklaSG5SaEF0MERXQ3FmMXZrMjBBc2h1Z3hFVzRoSzZxNmJfUUozcDlDY2pvNGZsaS11eUtpdThCTUJrbmVJaFdDWjdDUmRBU2hVNUpsWnFEMVhCd0g3N1YtdlFZZ2hvenB1MEdHeDZyVE1WVE9EeExPanRraW…
EUDA Health (EUDA) registers 947,963-share resale and outlines QB token platform risks - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPMmxtaUpjOWxkU2xnekRqcHE2V3FNTFBaSHl0Y1VIVFIxaE1fRDdVTFQzSGtSZnVPSTZJbEkxTHhnUGY4TGstYVV2LTJ0UGtpckFva2NyZTh5MjhiWEM2dnVtRVlvR3B5Z2xTY1J3QVQxUF9NQ0ItR1k5UkFkM29mZUNSTkhEN256bTV4ME…
EUDA — Frequently Asked Questions
What is the current share price of EUDA?
As of 2026-08-05 17:25 PDT, EUDA trades at $17.22 on NASDAQ/NYSE. Its 52-week range is $5.26 to $77.80.
Is EUDA a good stock to buy?
This page provides a data-driven analysis of EUDA, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.